The Impact of Chronic Medical Conditions on the Risk of Human Metapneumovirus Hospitalizations in New Zealand Adults, 2012-2015
- PMID: 40668093
- PMCID: PMC12265055
- DOI: 10.1093/infdis/jiaf226
The Impact of Chronic Medical Conditions on the Risk of Human Metapneumovirus Hospitalizations in New Zealand Adults, 2012-2015
Abstract
Background: Unlike influenza, information on the risk of human metapneumovirus (HMPV) infections in adults with chronic medical conditions (CMCs) is less robust.
Methods: The SHIVERS project (Southern Hemisphere Influenza and Vaccine Effectiveness Research and Surveillance) performed a population-based surveillance of acute respiratory illness hospitalizations in Auckland, New Zealand, from 2012 to 2015. In this analysis, we linked these surveillance data to population-based administrative data to estimate the age- and ethnicity-adjusted risk of HMPV-associated hospitalization during the study period among adults by certain CMCs: chronic obstructive pulmonary disease, asthma, congestive heart failure, coronary artery disease, cerebrovascular accidents, diabetes mellitus, and end-stage renal disease.
Results: Overall, HMPV hospitalization rates were significantly higher across all ages and ethnic groups among adults with CMCs than those without any condition. In imputed analysis, the CMC with the highest risk of HMPV hospitalization across age groups was congestive heart failure (incidence rate ratio [IRR] range, 7.0-23.0), followed by coronary artery disease (IRR range, 4.2-9.1) and chronic obstructive pulmonary disease (IRR range, 6.7-11.9) in adults aged ≥50 years. The CMC with the highest risk of HMPV hospitalization was congestive heart failure in Māori/Pacific adults and chronic obstructive pulmonary disease in non-Māori/Pacific adults. Adults with ≥2 CMCs had a higher risk than those without CMCs; the risk varied by age group and ethnicity.
Conclusions: Adults with specific or ≥2 CMCs are at increased risk of HMPV hospitalizations. Age and ethnicity affect this relationship for some CMCs but not all. Such populations may benefit from future HMPV prevention strategies.
Keywords: acute respiratory infection; adults; chronic medical conditions; human metapneumovirus; incidence.
© The Author(s) 2025. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Conflict of interest statement
Potential conflicts of interest . Q. S. H. is currently contracted by Icosavax, a member of the AstraZeneca Group, to conduct data analysis for this article. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Similar articles
-
The Burden of HMPV- and Influenza-Associated Hospitalizations in Adults in New Zealand Before and After the COVID-19 Pandemic, 2012-2023.J Infect Dis. 2025 Jul 16;232(Supplement_1):S47-S58. doi: 10.1093/infdis/jiaf150. J Infect Dis. 2025. PMID: 40668100 Free PMC article.
-
Respiratory Syncytial Virus and Human Metapneumovirus Respiratory Hospitalizations and Outcomes in Colorado Adults ≥50 Years of Age: 2016-2023.J Infect Dis. 2025 Jul 16;232(Supplement_1):S19-S28. doi: 10.1093/infdis/jiaf266. J Infect Dis. 2025. PMID: 40668095 Free PMC article.
-
Review: Knowledge Gained and Gaps in Understanding in the 25 Years Since Human Metapneumovirus Was First Identified as a Cause of Human Disease.J Infect Dis. 2025 Jul 16;232(Supplement_1):S1-S9. doi: 10.1093/infdis/jiaf187. J Infect Dis. 2025. PMID: 40668102 Free PMC article. Review.
-
Multicenter Cross-sectional Study on the Epidemiology of Human Metapneumovirus in Italy, 2022-2024, With a Focus on Adults Over 50 Years of Age.J Infect Dis. 2025 Jul 16;232(Supplement_1):S109-S120. doi: 10.1093/infdis/jiaf111. J Infect Dis. 2025. PMID: 40668103 Free PMC article.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
References
-
- Boivin G, Abed Y, Pelletier G, et al. Virological features and clinical manifestations associated with human metapneumovirus: a new paramyxovirus responsible for acute respiratory-tract infections in all age groups. J Infect Dis 2002; 186:1330–4. - PubMed
-
- Aminisani N, Wood T, Jelley L, Wong C, Huang QS. The burden of HMPV and influenza associated hospitalizations in adults in New Zealand, 2012–2015. J Infect Dis 2024; 230:933–43. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources